FBXW7 (F-box and WD40 domain protein 7) is a tumor suppressor frequently inactivated in human cancers. The precise molecular mechanisms by which FBXW7 exerts antitumor activity remain under intensive investigation and are thought to relate in part to FBXW7-mediated destruction of key cancer-relevant proteins. Enolase 1 (ENO1) possesses oncogenic activity and is often overexpressed in various human cancers, besides its critical role in glycolysis. However, the detailed regulatory mechanisms of ENO1 expression remain unclear. Here we show that the elevated expression of ENO1 was identified in FBXW7-depletion HCT116 cells through two-dimensional protein electrophoresis and mass spectrometry assays (2DE-MS). Subsequent western blotting and immunohistochemical assays confirmed that ENO1 expression reversely correlates with FBXW7 expression in several cells and colon cancer tissues. Furthermore, we show that FBXW7 physically binds to ENO1 and targets ENO1 for ubiquitin-mediated degradation. Functionally, we found that FBXW7 suppresses the ENO1-induced gene expression, lactate production, cell proliferation and migration. These findings suggest that ENO1 is a novel substrate of FBXW7, and its activity can be negatively regulated by FBXW7 at the posttranslational level. Our work provides a novel molecular insight into FBXW7-directed tumor suppression through regulation of ENO1. Enolase 1 (ENO1) is a conserved glycolytic enzyme that catalyze the formation of phosphoenolpyruvate from 2-phosphoglycerate, which generates ATP during glycolysis. 1,2 Several studies have shown that, besides its major role in glycolysis, ENO1 is a multifunctional protein participating in several physiological processes, including growth control, hypoxia tolerance and autoimmune activities. 1,3-5 Remarkably, accumulating evidence suggests that ENO1 can function as an oncogenic protein by promoting cell proliferation, invasion and metastasis. ENO1 expression is frequently increased in diverse tumors, including head and neck, 6 thyroid, 7 breast, 8 lung, 9,10 prostate, 11 colon and gastric cancer, 12,13 glioma 14 and cholangiocarcinoma. 15 Moreover, overexpression of ENO1 is positively associated with progression and poor prognosis in several tumors.
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The expression of ENO1 is regulated at multiple levels. Nuclear factor kappa B (NFκB) and hypoxia-inducible factor-1α (HIF-1α) are involved in the transcriptional activation of ENO1. 8, 16 MiR-206 may target ENO1 and inhibit the expression of ENO1. 17 Activation of the Src and MEK/ERK signal pathways upregulates ENO1 expression, 18 whereas retinoic acid reduces ENO1 at the protein level. 19 Although a lot of efforts have been made in studying the regulatory mechanism of ENO1 activity, the possibility that other factors might regulate ENO1 expression during tumorigenesis remains to be investigated.
FBXW7 (F-box and WD40 domain protein 7) is a conserved F-box WD40 protein and functions as a substrate recognition subunit of the SCF (SKP1/CUL1/F-box protein) E3 ubiquitin ligase. 20 FBXW7 targets a network of proteins with central roles in cell division, cell growth and differentiation for ubiquitination and proteasome degradation. As most FBXW7 substrates are potent oncoproteins, such as cyclin E, 21, 22 Notch, 23 mTOR, 24, 25 Aurora A, 26, 27 etc, FBXW7 represents a major tumor suppressor. Numerous cancer-associated mutations of FBXW7 have been found in various cancers [28] [29] [30] and loss of FBXW7 function results in tumorigenesis. 31 However, a detailed understanding of the full set of FBXW7 substrates and the mechanisms that link FBXW7 deficiency to tumorigenesis is still lacking.
In this present study to further investigate the suppressive role of FBXW7 in tumorigenesis, we used proteomics approach to globally identify FBXW7-regulated proteins in colon cancer cells. Differential expression of ENO1 protein in normal and FBXW7-deficient cells was first identified. Further studies indicated that FBXW7 is a novel regulator of ENO1 protein. FBXW7 physically bound to and facilitated the ubiquitination and degradation of ENO1. Consequently, the biological activity of ENO1 was inhibited by FBXW7. Our observations suggest that ENO1 has an important role in FBXW7-induced growth inhibition of cancer cells. − / − cells was prepared and then labeled with Cy2 and Cy5, respectively. 2-D electrophoresis was performed using Bergman's method as previously described. 13 Following 2-D electrophoresis, gels were scanned into a computer. The 2-D gel profile was analyzed using the PDQuest software (Bio-Rad). Finally, the differentially expressed protein spots were identified using the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) on a mass spectrometer (Voyager-DE PRO). 
MATERIALS AND METHODS
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Western Blotting
Cells were harvested and lysed in RIPA buffer (1% Triton X-100, 0.1% SDS, 50 mM Tris PH 7.5, 150 mM NaCl, 0.5% sodium deoxycholate, 10 mM NaF) supplemented with protease inhibitors (Roche). Lysates were clarified by centrifugation at 14 000 g for 20 min at 4°C. Protein concentration was then determined by the BCA Kit (Biyuntian). After incubation at 95°C for 5 min in SDS sample buffer, protein extracts were separated by 10% SDS-PAGE and then electroblotted onto PVDF membranes. The membranes were blocked with 5% (w/v) BSA in TBST for 2 h and then incubated with antibodies anti-FBXW7 (1:1000), anti-ENO1 (1:1000) and anti-β-actin (1:2000) at 4°C overnight. After three washes with TBST, the membranes were incubated for 1 h at room temperature in a 1:10 000 dilution of IgGhorseradish peroxidase secondary antibody (Sigma-Aldrich) and visualized with chemiluminescence (Pierce Protein Biology Products/Thermo Scientific, Rockford, IL, USA).
Coimmunoprecipitation Assay
Cells were seeded in 10-cm culture plates and treated with 10 μM MG132 for 6 h and then lysed in NP-40 lysis buffer. About 1-mg cell lysates were incubated with the indicated antibodies overnight at 4°C on a verticle roller. The lysates were incubated with 30 μl of Protein A/G agarose beads (Calbiochem) for 4 h and then the beads were washed four times with cold PBS. The immunoprecipitated proteins were then identified by western blotting. The membranes were immunoblotted with the corresponding primary antibodies.
Quantitative Real-Time PCR (qRT-PCR)
The total RNA was isolated using Trizol reagent (Invitrogen, USA). Total RNA was reversely transcribed by the SuperScript II Reverse Transcriptase (Invitrogen).The mRNA expression was determined by qRT-PCR using SYBR Green PCR Master Mix (Thermo). The primers sequences were as follows:
FBXW7 forward primer 5′-CGAACTCCAGTAGTATTGT GGACCT-3′ and reverse primer 5′-TTCTTTTCATTTTTGT TGTTTTTGTATAGA-3′; CCL20 forward primer 5′-GACTGCTGTGTTGGATACAC-3′ and reverse primer 5′-CTGAGGAGACGCACAATATA-3′; and GAPDH forward primer 5′-GCCGCATCTTCTTTTGCGT CGC-3′ and reverse primer 5′-TCCCGTTCTCAGCCTTGAC GGT-3′;
GAPDH was used as the reference gene. The relative levels of gene expression were represented as 2
. Experiments were repeated in triplicate.
Wound-Healing Assay
Cells were grown to confluence in six-well plates to a density of approximately 5 × 10 6 cells per well and denuded by dragging sterile plastic 200-μl micropipette tips through the center of the plate. Images were captured under a phasecontrast microscopy at 0 and 44 h.
Cell Proliferation Assay
The viability of cells was determined by assaying the reduction of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT). Briefly, cells were plated onto 96-well plates with 2 × 10 3 cells per well. At the indicated time, the medium was replaced by 100 μl medium and incubated with 10 μl MTT (5 mg/ml) for 4 h. The particles were dissolved with DMSO, and the absorbance was determined at 492 nm.
Lactate Assay
Cells were collected and dispersed using ultrasonic disintegrator and then the lysates were centrifuged at 2000 g for 15 min at 4°C. The supernatant was collected and total protein concentration was determined by the BCA Kit (Biyuntian). The level of lactic acid was measured using commercially available diagnostic kits according to the manufacturer's instructions (Nanjing Jiancheng Bioengineering Institute, Nanjing, China).
Immunohistochemistry and Scoring
A total of 50 samples of colorectal cancer tissues and corresponding adjacent non-cancerous tissues were obtained from patients undergoing surgical excision of tumors in Qilu Hospital of Shandong University (Jinan, China). The samples were fixed with 10% formalin and embedded in paraffin and then were sliced into 5-μm sections. The sections were deparaffinized in xylene and rehydrated through graded alcohol. After incubation in 0.3% H 2 O 2 and blocked with (Figures 1a and b) . Figures 1D-F) . Together, these results suggest that FBXW7 can downregulate ENO1 protein expression at the posttranscriptional level.
FBXW7 Promotes Proteasomal Degradation of the ENO1 Protein
As FBXW7 is an E3 ligase, we first evaluated whether FBXW7 could regulate ENO1 protein stability. The turnover of ENO1 protein in the HCT116 FBXW7 +/+ and FBXW7 − / − cells was measured, respectively, by cycloheximide (CHX) chase assay. The result showed that the half-life of ENO1 was significantly extended when FBXW7 expression is depleted, indicating that FBXW7 decreased ENO1 protein level by promoting its degradation (Figure 3a) . Then we determined whether the degradation of ENO1 by FBXW7 is through the proteasomedependent pathway. HCT116 FBXW7 +/+ and FBXW7 − / − cells were treated with the proteasome inhibitor MG132. Indeed proteasome inhibition caused a significant increase in ENO1 levels in HCT116 FBXW7 +/+ cells but not in HCT116 FBXW7
− / − cells ( Figure 3b ). As FBXW7-mediated degradation of most substrates occurs in a GSK3β-dependent manner, we examined whether FBXW7 targets ENO1 also in a GSK3β-dependent manner. Similar with the treatment of MG132, Gsk3β inhibitor treatment resulted in a significant increase in ENO1 levels in HCT116 FBXW7 +/+ cells but not in HCT116 FBXW7
− / − cells (Figure 3c ). To test whether FBXW7 ubiquitinates ENO1, HEK293T cells were transfected with Myc-tagged ubiquitin (Myc-ub) alone, in combination with WT FBXW7, FBXW7△F or shFBXW7 B. Immunoprecipitation with Myc-ub followed by ENO1 immunoblotting showed that overexpression of WT FBXW7 but not of FBXW7△F increased the ENO1 ubiquitination while knockdown expression of FBXW7 reduced the ENO1 ubiquitination (Figure 4a ). Additionally, we examined the ENO1 ubiquitination in HCT116 FBXW7 +/+ and FBXW7 − / − cells and also found that the ENO1 ubiquitination is decreased in FBXW7 − / − HCT116 cells (Figure 4b ). Together, these data indicate that FBXW7 acts as an E3 ligase and promotes ENO1 degradation through ubiquitin/proteosome pathway in a GSK3β-dependent manner. 
FBXW7 Physically Binds to ENO1
Next, we performed coimmunoprecipitation assay to determine whether ENO1 interacts with FBXW7. HEK293T cells were transiently transfected with Flag-tagged ENO1 alone or in combination with HA-tagged FBXW7. Lysates were immunoprecipitated with anti-Flag antibody and then probed for FBXW7 by anti-HA antibody. Western blotting analysis revealed that HA-tagged FBXW7 coimmunoprecipitated with Flag-tagged ENO1, indicating a physical interaction between the two proteins (Figure 5a) . Moreover, to determine whether endogenous FBXW7 could bind to ENO1, lysates of HCT116 FBXW7 +/+ cells were immunoprecipitated with anti-FBXW7 antibody and probed for ENO1 by anti-ENO1 antibody. Western blotting revealed that FBXW7 coprecipitated with endogenous ENO1 (Figure 5b ). These results demonstrate that FBXW7 binds to ENO1 and targets ENO1 for proteasomal degradation.
FBXW7 Negatively Regulates Biological Activities of ENO1
To determine the biological implications of FBXW7 in regulating ENO1 turnover, we monitored the effects of FBXW7 on ENO1-mediated cellular activities. We first analyzed whether FBXW7 regulated ENO1 target gene expression. As it is reported that chemokine CCL20 is a downstream target of FBXW7 targets ENO1 for its proteasomal degradation P Zhan et al ENO1 and can be upregulated by overexpression of ENO1 at the transcriptional level, 6 we examined the effect of FBXW7 on ENO1-mediated CCL20 expression. ENO1 expression was silenced by shRNA construct, respectively, in HCT116 FBXW7 +/+ and FBXW7 − / − cells. The levels of ENO1 in the different cell groups were first verified by western blotting (Figure 6a ). Then the CCL20 expression in these cells was measured by qRT-PCR. The results showed that depleting FBXW7 expression in HCT116 cells significantly increased CCL20 expression while silencing ENO1 blocked FBXW7 loss-induced CCL20 overexpression (Figure 6b ). Given the function of ENO1 as a glycolysis enzyme, we then examined whether FBXW7 alters the cellular lactic acid concentration in an ENO1-dependent manner. The results showed that knockdown of ENO1 significantly impaired the increase of the cellular lactic acid level induced by loss of FBXW7 expression ( Figure 6c ). Next, we explored whether FBXW7 affects the biological function of ENO1. MTT and woundhealing assay showed that overexpression of FBXW7 reduced the promoting effect of ENO1 overexpression on cell growth FBXW7 targets ENO1 for its proteasomal degradation P Zhan et al and migration (Figures 7a and b) . Similarly, ENO1 knockdown also alleviated FBXW7 loss-induced enhancement of cell migration (Figure 7c ). Taken together, these results suggest that FBXW7 negatively regulated ENO1-mediated cell biological function.
FBXW7 Negatively Correlates with the ENO1 Expression in Colon Cancer Tissues
To explore any clinical significance of the observation, we then analyzed the expression of FBXW7 and ENO1 in colon cancer tissues by immunohistochemistry. The negative correlation between FBXW7 and ENO1 was revealed in these tissues (Figures 8a and b) . This result is consistent with and further supports our above analyses that FBXW7 acts as a new negative regulator of ENO1.
DISCUSSION
FBXW7 represents a major tumor suppressor and has been firmly associated with tumor progression. As a physiological E3 ligase, the most common mechanism that FBXW7 exerts its tumor-suppressor function is targeting a network of oncoproteins, including cyclinE, 21, 32 Aurora A, 27,33,34 mTOR, 24 c-Myb, 35 etc., for degradation by the proteasome. Although an increasing number of FBXW7 substrates have been identified recently, a detailed understanding of a full set of FBXW7 substrates and how FBXW7 inactivation causes disease remains largely unknown. In this study, to further elucidate the functional targets of FBXW7, we screened differentially expressed proteins induced by loss of FBXW7 in HCT116 cells using quantitative proteomics techniques. Among the proteins whose expression was altered by deficiency of FBXW7, ENO1 was first identified and validated with further western blotting. In addition to its well-documented enzymatic role in glycolysis, ENO1 performs a variety of important cellular functions and has a critical role in physiological and pathophysiological process especially in carcinogenesis. 1 ENO1 has been considered to be a diagnostic marker for many kind of tumors, 9, 14, 36, 37 and overexpression of ENO1 is a common scenario in several cancers and is closely connected with tumor progression and poor clinical outcomes. 10, 13, 38 As ENO1 has an important role in tumorigenesis and tumor development, it will be important to further characterize the mechanisms through which ENO1 is regulated. Many reports have demonstrated that ENO1 can be regulated at different levels by multiple factors. For example, ENO1 can be transcriptionally activated by NFκB, 8 HIF-1α 4 and estrogen receptor (ER) α, 2,8 while it also can be downregulated by retinoic acid at the protein level. 39 Moreover, Yu et al 2 observed that estradiol prolongs ENO1 protein half-life and increases ENO1 protein accumulation via a posttranscriptional mechanism. However, the posttranslational mechanisms that is involved in ENO1 regulation were not clearly investigated.
In the present study, our proteomics analysis revealed that homologous depletion of FBXW7 in HCT116 cells led to an obvious increase of ENO1 protein, which suggested an involvement of FBXW7 in the regulation of ENO1 abundance. Further experiments confirmed that ENO1 is a new target of FBXW7 and is downregulated by FBXW7 for FBXW7 targets ENO1 for its proteasomal degradation P Zhan et al proteasome degradation. To our knowledge, this is the first study to report that ENO1 protein is regulated by the FBXW7 E3 ligase at the posttranslational level. We provided several lines of evidence to support our finding. First, FBXW7 knockdown increases the ENO1 protein level, whereas FBXW7 overexpression decreases ENO1 protein expression. Supportively, significantly negative correlation between FBXW7 and ENO1 was found in human colorectal cancer tissues. Second, FBXW7 knockout significantly prolongs the ENO1 half-life. Meanwhile, proteasome inhibitor MG132 blocks FBXW7 loss-induced ENO1 overexpression. Third, FBXW7 interacts with ENO1 and promotes ubiquitination of ENO1. Furthermore, we also investigated the effect of FBXW7 on the biological role of ENO1 and finally found that FBXW7 suppresses the ENO1 function of promoting the CCL20 gene expression, lactate generation and colon cancer cell proliferation and migration.
In summary, the data presented herein suggest that FBXW7 negatively regulates the activity of ENO1 by facilitating its ubiquitin-mediated proteasomal degradation. Our current findings not only identify a new target of FBXW7 but also uncover a novel regulatory mechanism of ENO1, which may help us further understand the roles of FBXW7 and ENO1 in cancer development.
